Up-regulation of secretory leukocyte protease inhibitor (SLPI) in the brain after ischemic stroke: Adenoviral expression of SLPI protects brain from ischemic injury

Molecular Pharmacology

Volumn 64, Issue 4, 2003, Pages 833-840

  Wang, Xinkang ^a,b   Li, Xiang ^a   Xu, Lin ^b   Zhan, Yutian ^b   Yaish Ohad, Shoshanit ^a   Erhardt, Joseph A ^a   Barone, Frank C ^a   Feuerstein, Giora Z ^a  

^a GLAXOSMITHKLINE   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INJURY; BRAIN ISCHEMIA; BRAIN PROTECTION; CONTROLLED STUDY; EPITHELIUM CELL; IMMUNOHISTOCHEMISTRY; MIDDLE CEREBRAL ARTERY OCCLUSION; MOLECULAR HYBRIDIZATION; NONHUMAN; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; STROKE; SUPPRESSION SUBTRACTIVE HYBRIDIZATION; VIRUS EXPRESSION; VIRUS RECOMBINANT;

ADENOVIRIDAE; AMINO ACID SEQUENCE; ANIMALS; BRAIN; BRAIN ISCHEMIA; CEREBRAL CORTEX; CEREBROVASCULAR ACCIDENT; DNA, COMPLEMENTARY; GENE EXPRESSION; GENE THERAPY; IMMUNOHISTOCHEMISTRY; MOLECULAR SEQUENCE DATA; PROTEINASE INHIBITORY PROTEINS, SECRETORY; PROTEINS; RATS; RNA, MESSENGER; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; SEQUENCE HOMOLOGY, AMINO ACID; UP-REGULATION;

EID: 0141569328     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.64.4.833     Document Type: Article

References (40)

1. Abe T, Kobayashi N, Yoshimura K, Trapnell BC, Kim H, Hubbard RC, Brewer MT, Thompson RC, and Crystal RG (1991) Expression of the secretory leukoprotease inhibitor gene in epithelial cells. J Clin Investig 87:2207-2215.
2. Ashcroft GS, Lei K, Jin W, Longenecker G, Kulkarni AB, Greenwell-Wild T, Hale-Donze H, McGrady G, Song XY, and Wahl SM (2000) Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing. Nat Med 6:1147-1153.
3. Barone FC, Price WJ, White RF, Willette RN, and Feuerstein GZ (1992) Genetic hypertension and increased susceptibility to cerebral ischemia. Neurosci Biobehav Rev 16:219-233.
4. Bohm B, Aigner T, Kinne R, and Burkhardt H (1992) The serine-protease inhibitor of cartilage matrix is not a chondrocytic gene product. Eur J Biochem 207:773-779.
5. Clark RK, Lee EV, Fish CJ, White RF, Price WJ, Jonak ZL, Feuerstein GZ, and Barone FC (1993) Development of tissue damage, inflammation and resolution following stroke: an immunohistochemical and quantitative planimetric study. Brain Res Bull 31:565-572.
6. del Zoppo G, Ginis I, Hallenbeck JM, Iadecola C, Wang X, and Feuerstein GZ (2000) Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol 10:95-112.
7. Erhardt JA, Legos JJ, Johanson RA, Slemmon JR, and Wang X (2000) Expression of PEP-19 inhibits apoptosis in PC12 cells. Neuroreport 11:3719-3723.
8. Fink E, Nettelbeck R, and Fritz H (1986) Inhibition of mast cell chymase by eglin c and antileukoprotease (HUSI-I). Indications for potential biological functions of these inhibitors. Biol Chem Hoppe-Seyler 367:567-571.
9. Fritz H (1988) Human mucus proteinase inhibitor (human MPI). Human seminal inhibitor I (HUSI-I), antileukoprotease (ALP), secretory leukocyte protease inhibitor (SLPI). Biol Chem Hoppe-Seyler 369:S79-S82.
10. Garcia JH, Liu KF, Yoshida Y, Lian J, Chen S, and del Zoppo GJ (1994) Influx of leukocytes and platelets in an evolving brain infarct (Wistar rat). Am J Pathol 144:188-199.
11. Gipson TS, Bless NM, Shanley TP, Crouch LD, Bleavins MR, Younkin EM, Sarma V, Gibbs DF, Tefera W, McConnell PC, et al. (1999) Regulatory effects of endogenous protease inhibitors in acute lung inflammatory injury. J Immunol 162:3653-3662.
12. Grobmyer SR, Barie PS, Nathan CF, Fuortes M, Lin E, Lowry SF, Wright CD, Weyant MJ, Hydo L, Reeves F, et al. (2000) Secretory leukocyte protease inhibitor, an inhibitor of neutrophil activation, is elevated in serum in human sepsis and experimental endotoxemia. Crit Care Med 28:1276-1282.
13. Hiemstra PS, Maassen RJ, Stolk J, Heinzel-Wieland R, Steffens GJ, and Dijkman JH (1996) Antibacterial activity of antileukoprotease. Infect Immun 64:4520-4524.
14. Ilzecka J and Stelmasiak Z (2002) Increased serum levels of endogenous protectant secretory leukocyte protease inhibitor in acute ischemic stroke patients. Cerebrovasc Dis 13:38-42.
15. Jaumann F, Elssner A, Mazur G, Dobmann S, and Vogelmeier C (2000) Transforming growth factor-beta1 is a potent inhibitor of secretory leukoprotease inhibitor expression in a bronchial epithelial cell line. Munich Lung Transplant Group. Eur Respir J 15:1052-1057.
16. Jin FY, Nathan C, Radzioch D, and Ding A (1997) Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell 88:417-426.
17. Kubes P and Ward PA (2000) Leukocyte recruitment and the acute inflammatory response. Brain Pathol 10:127-135.
18. Knight KR, Burdon JG, Cook L, Brenton S, Ayad M, and Janus ED (1997) The proteinase-antiproteinase theory of emphysema: a speculative analysis of recent advances into the pathogenesis of emphysema. Respirology 2:91-95.
19. Lentsch AB, Yoshidome H, Warner RL, Ward PA, and Edwards MJ (1999) Secretory leukocyte protease inhibitor in mice regulates local and remote organ inflammatory injury induced by hepatic ischemia/reperfusion. Gastroenterology 117:953-961.
20. Molhuizen HOF and Schalkwijk J (1995) Structural, biochemical and cell biological aspects of the serine proteinase inhibitor SKALP/elafin/ESI. Biol Chem Hoppe-Seyler 376:1-7.
21. Nakamura A, Mori Y, Hagiwara K, Suzuki T, Sakakibara T, Kikuchi T, Igarashi T, Ebina M, Abe T, Miyazaki J, et al. (2003) Increased susceptibility to LPS-induced endotoxin shock in secretory leukoprotease inhibitor (SLPI)-deficient mice. J Exp Med 197:669-674.
22. National Institutes of Health (1996) Guide for the Care and Use of Laboratory Animals. DHEW Publication no. (NIH) 85-23, revised 1996. National Institutes of Health, Bethesda, MD.
23. Ohlsson K, Bergenfeldt M, and Bjork P (1988) Functional studies of human secretory leukocyte protease inhibitor. Adv Exp Med Biol 240:123-131.
24. Schneider A, Martin-Villalba A, Weih F, Vogel J, Wirth T, and Schwaninger M (1999) NF-kappaB is activated and promotes cell death in focal cerebral ischemia. Nat Med 5:554-559.
25. Shimakura A, Kamanaka Y, Ikeda Y, Kondo K, Suzuki Y, and Umemura K (2000) Neutrophil elastase inhibition reduces cerebral ischemic damage in the middle cerebral artery occlusion. Brain Res 858:55-60.
26. Shine N, Konopka K, and Duzgunes N (1997) The anti-HIV-1 activity associated with saliva. J Dental Res 76:634-640.
27. Song X, Zeng L, Jin W, Thompson J, Mizel DE, Lei K, Billinghurst RC, Poole AR, and Wahl SM (1999) Secretory leukocyte protease inhibitor suppresses the inflammation and joint damage of bacterial cell wall-induced arthritis. J Exp Med 190:535-542.
28. Stetler G, Brewer MT, and Thompson RC (1986) Isolation and sequence of a human gene encoding a potent inhibitor of leukocyte proteases. Nucleic Acids Res 14: 7883-7896.
29. Tanaka N, Fujioka A, Tajima S, Ishibashi A, and Hirose S (2000) Elafin is induced in epidermis in skin disorders with dermal neutrophilic infiltration: interleukin-1 beta and tumour necrosis factor-alpha stimulate its secretion in vitro. Br J Der. matol 143:728-732.
30. Thompson RC and Ohlsson K (1986) Isolation, properties and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci USA 83:6692-6696.
31. Tomee JF, Koeter GH, Hiemstra PS, and Kauffman HF (1998) Secretory leukoprotease inhibitor: a native antimicrobial protein presenting a new therapeutic option? Thorax 53:114-116.
32. Wang H, Zhan Y, Xu L, Feuerstein GZ, and Wang X (2001) Use of suppression subtractive hybridization for differential gene expression in stroke: discovery of CD44 gene expression and localization in permanent focal stroke in rats. Stroke 32:1020-1027.
33. Wang X and Feuerstein GZ (2000) Role of immune and inflammatory mediators in CNS injury. Drug News Perspect 13:133-140.
34. Wang X, Li X, Yaish-Ohad S, Sarau HM, Barone FC, and Feuerstein GZ (1999) Molecular cloning and expression of the rat monocyte chemotactic protein-3 gene: a possible role in stroke. Mol Brain Res 71:304-312.
35. Wang X, Xu L, Wang H, Grzanna R, Zhan Y, Knabb RM, Luettgen JM, Bozarth TA, Galemmo RA, Wong PC, et al. (2003) Inhibition of factor Xa reduces ischemic brain damage after thromboembolic stroke in rats. Stroke 34:468-474.
36. Wang X, Yue TL, White RF, Barone FC, and Feuerstein GZ (1995) Transforming growth factor-beta 1 exhibits delayed gene expression following focal cerebral ischemia. Brain Res Bull 36:607-609.
37. Ward PA and Lentsch AB (2002) Endogenous regulation of the acute inflammatory response. Mol Cell Biochem 234-235:225-228.
38. Xia Y, Chen S, Wang Y, Mackman N, Ku G, Lo D, and Feng L (1999) RelB modulation of IkappaBalpha stability as a mechanism of transcription suppression of interleukin-1alpha (IL-1alpha), IL-1beta and tumor necrosis factor alpha in fibroblasts. Mol Cell Biol 19:7688-7696.
39. Xu L, Zhan Y, Wang Y, Feuerstein GZ, and Wang X (2002) Recombinant adenoviral expression of dominant negative IkappaBalpha protects brain from cerebral ischemic injury. Biochem Biophys Res Commun 299:14-17.
40. Zhu J, Nathan C, Jin W, Sim D, Ashcroft GS, Wahl SM, Lacomis L, Erdjument-Bromage H, Tempst P, Wright CD, et al (2002) Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell 111:867-878.